@piratefoxy @andref1989 @rodimusprime Also patent protection schemes (some of which might get resolved in next decade) https://t.co/zHEPcC46Ap
Publication: Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition. Chen BK, Yang YT, Bennett CL. Drugs. 2018 Nov;78(17):1777-1781. https://t
RT @GwPolicy: This new piece #GwPolicy’s Tony Yang & colleagues on why #biosimilars have not yet produced larger savings in the US focuses…
This new piece #GwPolicy’s Tony Yang & colleagues on why #biosimilars have not yet produced larger savings in the US focuses on #patent disputes, #PBMs, aggressive direct-to-consumer advertising and lack of #interchangeability. https://t.co/A1S8lAE0aO
This new piece on why #biosimilars have not yet produced larger savings in the US focuses on #patent disputes, in addition to anti-competitive bundling deals with #PBMs. aggressive direct-to-consumer advertising and lack of #interchangeability. @RANDHealth